Unraveling Neurological Diseases
Model organisms reveal critical insights into Batten disease, a pediatric neurodegenerative disorder.
CLN3 Batten disease, a pediatric lysosomal storage disorder, affects approximately 1 in 100,000 individuals, making it the most common pediatric neurodegenerative disorder worldwide. Yet, a lack of etiological insights and translatable biomarkers has significantly slowed therapy development.
In this webinar, we discuss a novel multiomics study of a Yucatan Minipig model organism, powered by Seer’s Proteograph™ workflow, and the novel CLN3 disease-related biomarkers and molecular insights discovered.
Helping advance neurological disease treatment research for targeted therapies, this is the most exhaustive in-depth multiomics profiling ever conducted on serum from a porcine model with thousands of proteins, 10,000+ peptides, and metabolome data.
This webinar is best for:
- Proteomics and multiomics research professionals.
- Scientists studying neurodegenerative disorders, biofluids, and/or model organisms.
- General scientific community.
Things you’ll learn about:
- Seer’s Proteograph™ XT and nanoparticle-based workflow.
- How Sanford Research discovered novel CLN3-related biomarkers and molecular insights in a Yucatan Minipig disease model, utilizing a novel multiomics approach.
- The Proteograph’s species-agnostic capabilities for processing low-volume samples.
Featured Speakers
Jon Brudvig, Ph.D. Director of Discovery Research and Gene Therapy, Amicus Therapeutics
Aaron Gajadhar, Ph.D. Director of Strategic Applications, Seer Inc.
Watch Webinar On-Demand
Fill out the form to watch the webinar.